|
- 现金
- 205 元
- 精华
- 1
- 帖子
- 56
- 注册时间
- 2003-2-12
- 最后登录
- 2010-7-20
|
1楼
发表于 2004-2-4 03:24
Epimmune (EPMN) Earns Milestone Payment From Genencor International (GCOR) On Hepatitis B Vaccine Program
SAN DIEGO, Feb. 2 /PRNewswire-FirstCall/ -- Epimmune Inc. today announced that it has earned a milestone payment from Genencor International, Inc. as a result of Genencor filing an Investigational New Drug application (IND) for a DNA-based therapeutic vaccine to treat Hepatitis B. Genencor expects trials to begin later this month under the IND. Epimmune collaborated on the design and preclinical development of the vaccine under its collaboration agreement with Genencor.
Dr. Emile Loria, President and CEO of Epimmune said, "Achievement of this milestone represents a continuation of Epimmune's transition from a research based to a product and clinical development based company. With Genencor's anticipated launch this month of the Phase I study, their therapeutic Hepatitis B vaccine will become the fifth vaccine product candidate incorporating Epimmune technology to enter human clinical testing, including three ongoing trials we are conducting ourselves."
In July 2001, pursuant to a license agreement, Genencor exclusively licensed Epimmune's epitope and PADRE(R) technologies and related intellectual property rights on a worldwide basis for vaccines to treat or prevent hepatitis B (HBV), hepatitis C (HCV) and human papilloma virus (HPV) and the two companies entered into a collaboration agreement focused on development of therapeutic vaccines for the three viral indications. The collaboration agreement shall conclude in August 2004, unless terminated earlier by Genencor. Genencor also took an initial 10% equity stake in Epimmune at that time.
About Epimmune Inc.
Epimmune Inc., based in San Diego, is focused on the development of pharmaceutical products using multiple epitopes to specifically activate the body's immune system. Epitopes, critical signaling molecules, stimulate the T cell arm of the immune system to respond to specific regions of cancer cells or infectious agents. By combining multiple, selected epitopes into a single drug candidate, the immune response can be both targeted and optimized for strength. Epimmune's therapeutic drug candidates have been designed to treat disease by stimulating the body's immune system to respond aggressively to infections such as HIV, hepatitis C virus and hepatitis B virus, and tumors such as breast, colon, lung and prostate. The Company's preventative drug candidates have been designed to protect against disease by teaching the body's immune system to react quickly when exposed to infectious agents. Epimmune's technology can also be used to identify and potentially eliminate undesirable reactions to therapeutic drugs or consumer products by modifying specific epitopes to suppress the unwanted immune response. For more information on Epimmune, visit http://www.epimmune.com/ .
Forward-Looking Statements
This press release includes forward-looking statements that reflect Epimmune's management's current views of future events, including statements regarding the benefits of the epitope and PADRE(R) technologies, the use of these technologies in products being developed by Genencor, the safety and efficacy of epitope-based products in humans and the timing for initiating Phase I safety and immunogenicity testing of Genencor's therapeutic Hepatitis B vaccine. Actual results may differ materially from the above forward- looking statements due to a number of important factors such as risks associated with the utility of the epitope and PADRE(R) technologies in eliciting an immune response with vaccines, the utility of Genencor's technology, the development and commercialization efforts of Genencor, the ability of Epimmune to maintain its collaboration agreement with Genencor, reliance on licensees and collaborators, including, but not limited to Genencor, the timing of conducting human clinical trials, the regulatory approval process and the possibility that testing may reveal undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products. These factors are more fully discussed in the Company's Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2002, the Company's Quarterly Report on Form 10-Q filed with the SEC for the quarter ended September 30, 2003 and other periodic reports filed with the Securities and Exchange Commission. Epimmune expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
For further information, please contact: Robert De Vaere, VP, Finance & Admin. & CFO of Epimmune Inc., +1-858-860-2500; or Linda Chien, General Information, +1-310-407-6547, [email protected], or Tricia Ross, Investor/Analyst Information, +1-310-407-6540, [email protected], both of Financial Relations Board, for Epimmune Inc.
Epimmune Inc.
CONTACT: Robert De Vaere, VP, Finance & Admin. & CFO of Epimmune Inc.,+1-858-860-2500; or Linda Chien, General Information, +1-310-407-6547,[email protected], or Tricia Ross, Investor/AnalystInformation, +1-310-407-6540, [email protected], both ofFinancial Relations Board, for Epimmune Inc.
Web site: http://www.epimmune.com/
|
|
)
